HOME
French National Research Agency Success Stories
Conferences for partnering opportunities
Since 2005, the French National Research Agency -ANR- has launched specific calls for proposals dedicated to biotech technology transfer and academic-industrial partnerships.Following a global strategy to mix efficiently academic and industrial partners' R&D culture, ANR has succeeded in creating the condition for an operational technology transfer process leading to real success stories.
ANR supports the whole technology transfer continuum from the early discoveries through the proof-of-concept validation and, further, clinical trials and industrial developments. From 2005 to 2007, ANR launched two dedicated programmes: the "Emergence" programme and the "Innovative Biotechnology Network" programme.
The "Emergence" programme was open to academic partners and consortiums in order to fund the proof-of-concept process, based on a rigorous evaluation of the projects' economic perspective, intellectual property background and scientific innovation. This programme allowed the emergence and the funding of ground-breaking technologies from their early stage up to their industrial uptake.
The "Innovative Biotechnology Network (RIB)" programme consisted in funding the technology transfer projects between academic and industrial partners. The selected projects had to be coordinated by industrial partners in order to secure the innovation developments with a clear market-oriented strategy.
Jointly, these programmes give SME and academic partners the opportunity to exchange technological solutions and best practices in a 'win-win' relation leading to a successful and accelerated development of their R&D programmes.
Considering existing biotech innovation support actions, what are the specificities of Emergence and Innovative Biotechnology Network -RIB- programmes led by the French National Research Agency (ANR)?
Emergence programme added value is to fill the funding gap surrounding the necessary maturation phase between promising scientific results and the proof-of-concept validation, making them ready for industrial development.
This programme is complemented by the RIB programme that goes a step further: it allows the financial support of technologies that have succeeded in the first steps of their maturation process and that need support to validate their proof-of-concept and, furthermore their next development steps such as clinical trials or first ready-to-market products development.
What do you think of EuroBIO 2009's ability to cluster partners on such programmes?
We do think that EuroBIO 2009 is a real opportunity to maximize the exchanges around such biotech innovation programmes. During this event, we will propose a whole-day "Key Partner Meeting" - based on proven success stories - and dedicated conferences, with more than 60 projects' leaders ready to create new valuable partnerships with actors interested in their products or expertises.
Emergence and RIB - Programme Officer
French National Research Agency (ANR)
Chairwoman session "Conferences for partnering opportunities
Thursday, September 24th
A WHOLE-DAY SESSION ON ANR KEY PARTNER MEETING AND DEDICATED CONFERENCES FOR PARTNERING OPPORTUNITIES
8h30 : Accueil des participants
9h00-9h15 : Introduction
M. Patrick CHAUSSEPIED | Directeur du Département Biologie Santé, ANR
9h15-9h40
Création de valeur pendant et à l'issue des projets partenariaux : les soutiens proposés par la Commission Européenne
M. Stéphane HOGAN | DG Research - Commission Européenne
9h40-12h30
Success-stories ANR en AGRO-ENVIRONNEMENT
- «Nouvelle technologie de « finishing » de génomes complexes par nalyse discriminative de signature clonale (DACS) : application au séquençage du chromosome 7 de la tomate»
Société COGENICS - Programme RIB 2005
- «Préindustrialisation d'un procédé de consolidation des sols par bio-calcification in situ»
Société Soletanche-Bachy - Programme RIB 2005
- «Développement d'un bioprocédé de production de propylène glycol»
Société METabolic EXplorer - Programme RIB 2005
- «Développement d'un procédé biotechnologique de production d'inoculum endomycorrhizien et détermination des conditions de son exploitation comme biofertilisant utilisé dans le cadre d'une agriculture durable»
Société Agronutrition SAS - Programme RIB 2005
Success-stories ANR en OUTILS BIOLOGIQUES DE RECHERCHE
- «Validation d'un modèle in vitro de barrière hémato-encéphalique »
Institut Cochin, INSERM U567, Paris - Programme Emergence 2006
- «Validation de nouveaux substrats de culture cellulaire pour criblage phénotypique haut débit »
Institut Curie, UMR 144, Paris - Programme Emergence 2006
- «Détection Electrochimique en Temps réel de Séquences Cibles d'Acides Nucléiques»
Laboratoire d'Electrochimie Moléculaire - Université Paris 7 - Programme Emergence 2006
- «Ultra Bright BioChips»
Société Genewave SAS - Programme RIB 2005
12h30-14h00
Déjeuner-buffet partenarial et exposition des posters projets (Zone Exposants- Network Area )
14h15-14h40
Création de valeur au sein des PME innovantes et relais de croissance par l'intermédiaire des financements publics
M. Philippe POULETTY | DG de Truffle Capital
14h40-17h30
Success-stories ANR en THERAPEUTIQUE
- «Traitement de la Progeria et d'autres états physiologiques ou pathologiques avec persistance de protéines prénylées : approche pharmacologique»
Laboratoire de Génétique Moléculaire, Marseille - Programme Emergence 2006
- «Solution gélifiante composite pour l'embolisation de pathologies veineuses»
Service de Radiologie / Neuroradiologie, Hôpital Lariboisière AP-HP Paris - Programme Emergence 2006
- «Biothérapie et reconstruction osseuse: développement de technologies chirurgicales associant de nouvelles ostéo-synthèses résorbables et des biomatériaux durcissants injectables innovants»
Société Biomatlante - Programme RIB 2005
- «Targeted Multi Therapy - Multi Thérapie Interstitielle Focalisée»
Centre d'Etudes et de Recherches Médicales d'Archamps (CERMA) - Programme RIB 2005
- «Thérapie d'immunodéficiences sévères combinées (SCID) par chirurgie sur ADN»
Société Cellectis SA - Programme RIB 2005
- «Développement d'un véhicule de vaccination nanoparticulaire, synthétique et biodégradable»
Société PHUSIS - Programme RIB 2005
Success-stories ANR en DIAGNOSTIC
- «Dispositif de détection précoce et de monitoring des altérations tissulaires induites au cours des états septiques graves par cartographie du pH intra-muqueux (pHim) gastrique»
Centre de Photomedecine du CHU de Lille - Programme RIB 2005
- «Biothérapie à l'aide d'anticorps monoclonaux anti CD-71 dans le traitement des tumeurs malignes: application au mélanome métastatique de la choroïde»
Société MAT Biopharma - Programme RIB 2005
17h30-17h45 : Conclusion
Mlle Aude SIRVEN | Responsable Programmes RIB/Emergence, Département Biologie Santé, ANR
